Literature DB >> 29020561

Saving Life, Limb, and Eyesight: Assessing the Medical Rules of Eligibility During Armed Conflict.

Michael L Gross1.   

Abstract

Medical rules of eligibility permit severely injured Iraqi and Afghan nationals to receive care in Coalition medical facilities only if bed space is available and their injuries result directly from Coalition fire. The first rule favors Coalition soldiers over host-nation nationals and contradicts the principle of impartial, needs-based medical care. To justify preferential care for compatriots, wartime medicine invokes associative obligations of care that favor friends, family, and comrades-in-arms. Associative obligations have little place in peacetime medical care but significantly affect wartime medicine. The second rule suggests liability for collateral harm that is unsupported by international law and military ethics. Absent liability, there are pragmatic reasons to offer medical care to injured local civilians if it quells resentment and cements support for Coalition forces. In contrast to peacetime medicine, military necessity and associative obligations outweigh distributive principles based on medical need during war.

Keywords:  law; moral theory; philosophy; rationing/resource allocation; right to health care

Mesh:

Year:  2017        PMID: 29020561     DOI: 10.1080/15265161.2017.1365186

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


  2 in total

1.  Ethical challenges experienced by UK military medical personnel deployed to Sierra Leone (operation GRITROCK) during the 2014-2015 Ebola outbreak: a qualitative study.

Authors:  Heather Draper; Simon Jenkins
Journal:  BMC Med Ethics       Date:  2017-12-19       Impact factor: 2.652

2.  Ethical challenges faced by French military doctors deployed in the Sahel (Operation Barkhane): a qualitative study.

Authors:  Antoine Lamblin; Clément Derkenne; Marion Trousselard; Marie-Ange Einaudi
Journal:  BMC Med Ethics       Date:  2021-11-19       Impact factor: 2.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.